
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
The analysis indicates that PepGen Inc. has demonstrated a robust dose-dependent increase in splicing correction in its FREEDOM-DM1 trial, particularly noting a nearly four-fold increase in oligonucleotide enrichment in muscle tissue as the dosage increased from 5 mg/kg to 10 mg/kg. This efficacy data, with a splicing correction rate of 29.1%, exceeds the generally accepted therapeutic threshold of 25-27%, reinforcing the potential therapeutic benefits of the Enhanced Delivery Oligonucleotide (EDO) platform. Furthermore, the absence of safety issues reported while testing higher doses signals a strong outlook for PepGen’s pipeline products, particularly PGN-EDO51, which could lead to a best-in-class position within the DM1 landscape.
Bears say
PepGen Inc. reported a significant net loss of $22 million or $0.68 per share in the fourth quarter of 2024, which raises concerns about its financial stability as it continues to develop its pipeline products, particularly PGN-EDO51. The company has lowered its probability of success for PGN-EDO51 from 40% to 25% due to safety concerns regarding kidney function, particularly related to reductions in estimated glomerular filtration rate (eGFR), which diminishes investor confidence in its clinical viability and potential market success. Additionally, substantial risks remain regarding the potential failure of PGN-EDO51 in clinical trials, securing regulatory approvals in the US and EU, and meeting peak commercial revenue expectations, all of which could adversely impact the company's financial performance and outlook.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares